Abstract
INTRODUCTION
The relationship between cerebrovascular disease (CVD) and amyloid beta (Aβ) in Alzheimer’s disease (AD) is understudied. We hypothesized that magnetic resonance imaging (MRI)–based CVD biomarkers—including cerebral microbleeds (CMBs), lacunar infarction, and white matter hyperintensities (WMHs)—would correlate with Aβ positivity on positron emission tomography (Aβ-PET).
METHODS
We cross-sectionally analyzed data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, N = 1352). Logistic regression was used to calculate odds ratios (ORs), with Aβ-PET positivity as the standard-of-truth.
RESULTS
Following adjustment, WMHs (OR = 1.25) and superficial CMBs (OR = 1.45) remained positively associated with Aβ-PET positivity (p < 0.001). Deep CMBs and lacunes exhibited a varied relationship with Aβ-PET in cognitive subgroups. The combined diagnostic model, which included CVD biomarkers and other accessible measures, significantly predicted Aβ-PET (pseudo-R2 = 0.41).
DISCUSSION
The study highlights the translational value of CVD biomarkers in diagnosing AD, and underscores the need for more research on their inclusion in diagnostic criteria. ClinicalTrials.gov: ADNI-2 (NCT01231971), ADNI-3 (NCT02854033).
Highlights
Cerebrovascular biomarkers linked to amyloid beta (Aβ) in Alzheimer’s disease (AD).
White matter hyperintensities and cerebral microbleeds reliably predict Aβ-PET positivity.
Relationships with Aβ-PET vary by cognitive stage.
Novel accessible model predicts Aβ-PET status.
Study supports multimodal diagnostic approaches.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Matthew D. Howe,
Megan R. Caruso,
Masood Manoochehri,
Zachary J. Kunicki,
Sheina Emrani,
James L. Rudolph,
Edward D. Huey,
Stephen P. Salloway,
Hwamee Oh,
for the Alzheimer’s Disease Neuroimaging Initiative | September 2, 2024